Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 2 Interventional Results available

A Study of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov ID: NCT05169684

Public ClinicalTrials.gov record NCT05169684. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Open-label, Randomized Controlled Trial of BMS-986218 or BMS-986218 Plus Nivolumab in Combination With Docetaxel in Participants With Metastatic Castration-resistant Prostate Cancer

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to assess the safety, efficacy, tolerability, and toxicity of docetaxel alone, in combination with BMS-986218, or in combination with nivolumab plus BMS-986218 in men who have metastatic castration-resistant prostate cancer (mCRPC) that progressed after novel antiandrogen therapy and have not received chemotherapy for mCRPC.

Study identification

NCT ID
NCT05169684
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 2
Lead sponsor
Bristol-Myers Squibb
Industry
Enrollment
10 participants

Conditions and interventions

Interventions

Biological · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 13, 2022
Primary completion
Dec 5, 2023
Completion
Dec 5, 2023
Last update posted
Jun 9, 2025

2022 – 2023

United States locations

U.S. sites
25
U.S. states
17
U.S. cities
25
Facility City State ZIP Site status
Arizona Oncology - Tucson - Wilmot Road Location Tucson Arizona 85711-2701
Kaiser Permanente Los Angeles Medical Center Los Angeles California 90027-5969
Rocky Mountain Cancer Centers - Littleton Littleton Colorado 80120-4413
Yale School Of Medicine New Haven Connecticut 06510-3206
Medical Oncology Hematology Consultants - Newark Newark Delaware 19713-2055
The Winship Cancer Institute of Emory University Atlanta Georgia 30322-1013
Local Institution - 0004 Marietta Georgia 30060
The University of Chicago Medical Center - Duchossois Center for Advanced Medicine Chicago Illinois 60637-1426
University Of Iowa Hospitals And Clinics Iowa City Iowa 52242
The Johns Hopkins Hospital Baltimore Maryland 21287
Washington University School of Medicine in St. Louis St Louis Missouri 63110-1010
Local Institution - 0006 New York New York 10032-3729
Duke Cancer Institute Durham North Carolina 27710
Oncology Hematology Care, Inc. - Eastgate Cincinnati Ohio 45245-1995
Willamette Valley Cancer Institute Eugene Oregon 97477
Texas Oncology-Beaumont Mamie McFaddin Ward Cancer Center Beaumont Texas 77702
Texas Oncology Bedford Texas 76022-6920
Texas Oncology - Denton North Denton Texas 76201-4315
Texas Oncology Flower Mound Texas 75028
Texas Oncology - Fort Worth Cancer Center Fort Worth Texas 76104-2150
The University of Texas - MD Anderson Cancer Center - Genitourinary (GU) Cancer Center Houston Texas 77030-4004
Texas Oncology - McKinney McKinney Texas 75071-8106
Texas Oncology- Tyler Tyler Texas 75702-8363
Local Institution - 0056 Hampton Virginia 23666-5963
Medical College of Wisconsin Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05169684, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 9, 2025 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05169684 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →